Gilead Wins Key Patent Rights Suit Over HIV Prevention Drug PrEPnews2023-05-09T17:34:57+00:00May 9th, 2023|The New York Times|
The Only H.I.V. Vaccine in Advanced Trials Has Failed. What Now?news2023-01-18T21:26:06+00:00January 18th, 2023|The New York Times|
How Anthony Fauci Quietly Shocked AIDS Activistsnews2022-12-31T14:00:06+00:00December 31st, 2022|The New York Times|
Un nuevo tratamiento contra el VIH ha probado ser un éxito. ¿Será accesible en África?news2022-09-30T09:00:20+00:00September 30th, 2022|The New York Times|
A New Shot Guards Against H.I.V., but Access for Africans Is Uncertainnews2022-09-27T07:00:12+00:00September 27th, 2022|The New York Times|
McKinsey Guided Companies at the Center of the Opioid Crisisnews2022-06-29T23:24:22+00:00June 29th, 2022|The New York Times|
Seeking Covid Pills, Poor Nations Fear Repeat of AIDS Crisisnews2022-05-09T01:11:48+00:00May 9th, 2022|The New York Times|
Este no es el fin de la pandemia del coronavirus. Veamos lo que pasó con el sidanews2022-02-18T09:00:06+00:00February 18th, 2022|The New York Times|
The Moral Danger of Declaring the Pandemic Over Too Soonnews2022-02-17T16:14:42+00:00February 17th, 2022|The New York Times|
In South Africa, Success Against H.I.V. Offers Hopenews2022-01-11T14:59:11+00:00January 11th, 2022|The New York Times|
